Application of Newcastle Disease Virus in the Treatment of Human and Canine Mammary Cancer

被引:1
作者
Coleto, Arlinda Flores [1 ]
Fonseca, Belchiolina Beatriz [2 ]
Medeiros-Ronchi, Alessandra Aparecida [1 ]
机构
[1] Univ Fed Uberlandia, Fac Vet Med, Lab Vet Pathol, Mato Grosso Ave,3289-Bloco 2S, Umuarama, MG, Brazil
[2] Univ Fed Uberlandia, Postgrad Program Genet & Biochem, Umuarama, MG, Brazil
关键词
Mammary; Neoplasm; Newcastle disease virus; Oncology; HEMAGGLUTININ-NEURAMINIDASE; ONCOLYTIC VIRUS; AF2240; STRAIN; CELLS; COMBINATION; APOPTOSIS; PATHWAYS; PATIENT; IMMUNE; TRIAL;
D O I
10.29261/pakvetj/2024.241
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Breast cancer is the most prevalent form of tumor worldwide and the leading cause of cancer among women globally. Similarly, mammary tumors are also common in canines, with a majority of them unfortunately being malignant. While chemotherapy is one of the most frequently employed treatments, it often comes with significant side effects. Consequently, alternative therapies are under investigation, including oncolytic viruses. The Newcastle disease virus (NDV) stands out due to its capacity to selectively target and destroy tumor cells while preserving healthy tissue, as well as its ability to trigger a robust antitumor immune response. Numerous studies support the utilization of NDV in treating various cancer types, ranging from brain tumors to gastrointestinal tract neoplasms. Other researches have also yielded promising results in the treatment of mammary neoplasms. This review aims to compile information about NDV and its application in oncolytic virotherapy for the study and treatment of human breast cancer and canine mammary tumors, employing cell lines, animal models, and clinical trials.
引用
收藏
页码:547 / 554
页数:8
相关论文
共 76 条
  • [1] Newcastle disease virus degrades HIF-1α through proteasomal pathways independent of VHL and p53
    Abd-Aziz, Noraini
    Stanbridge, Eric J.
    Shafee, Norazizah
    [J]. JOURNAL OF GENERAL VIROLOGY, 2016, 97 : 3174 - 3182
  • [2] Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy
    Adelfinger, Marion
    Bessler, Simon
    Frentzen, Alexa
    Cecil, Alexander
    Langbein-Laugwitz, Johanna
    Gentschev, Ivaylo
    Szalay, Aladar A.
    [J]. VIRUSES-BASEL, 2015, 7 (07): : 4075 - 4092
  • [3] Inhibitory and Apoptosis-Inducing Effects of Newcastle Disease Virus Strain AF2240 on Mammary Carcinoma Cell Line
    Ahmad, Umar
    Ahmed, Ismaila
    Keong, Yong Yoke
    Abd Manan, Nizar
    Othman, Fauziah
    [J]. BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [4] Ahmed I., 2014, Journal of Commerce, V6, P1
  • [5] 2-Deoxyglucose and Newcastle Disease Virus Synergize to Kill Breast Cancer Cells by Inhibition of Glycolysis Pathway Through Glyceraldehyde3-Phosphate Downregulation
    Al-Shammari, Ahmed Majeed
    Abdullah, Amer Hasan
    Allami, Zainab Majid
    Yaseen, Nahi Y.
    [J]. FRONTIERS IN MOLECULAR BIOSCIENCES, 2019, 6
  • [6] Al-Shammari AM, 2022, Bulgarian J Vet Med.
  • [7] Hexokinase inhibition using D-Mannoheptulose enhances oncolytic newcastle disease virus-mediated killing of breast cancer cells
    Al-Ziaydi, Ahmed Ghdhban
    Al-Shammari, Ahmed Majeed
    Hamzah, Mohammed, I
    Kadhim, Haider Sabah
    Jabir, Majid Sakhi
    [J]. CANCER CELL INTERNATIONAL, 2020, 20 (01)
  • [8] Evaluation of a Recombinant Newcastle Disease Virus Expressing Human IL12 against Human Breast Cancer
    Amin, Zahiah Mohamed
    Ani, Muhamad Alhapis Che
    Tan, Sheau Wei
    Yeap, Swee Keong
    Alitheen, Noorjahan Banu
    Najmuddin, Syed Umar Faruq Syed
    Kalyanasundram, Jeevanathan
    Chan, Soon Choy
    Veerakumarasivam, Abhi
    Chia, Suet Lin
    Yusoff, Khatijah
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)
  • [9] Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro
    Burke, Shannon
    Shergold, Amy
    Elder, Matthew J.
    Whitworth, Justine
    Cheng, Xing
    Jin, Hong
    Wilkinson, Robert W.
    Harper, James
    Carroll, Danielle K.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (06) : 1015 - 1027
  • [10] Cejalvo T, 2018, CANCER RES, V78, P4891, DOI [10.1158/0008-5472.CAN-17-3754, 10.1158/0008-5472.can-17-3754]